Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch ...

Eye health company Bausch & Lomb is recalling some of its intraocular lenses over possible safety concerns. The voluntary ...

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, ...

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

Bausch Health Companies Inc. BHC slipped 2.4% to $6.83 in pre-market trading. Bausch Health announced the pricing of upsized ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $17.00 ...

Bausch + Lomb has initiated a voluntary recall of its enVista platform intraocular lenses (IOLs) following reports of TASS.

See reviews below to learn more or submit your own review. Bausch & Lomb has manufactured eye health products and vision care solutions since 1853. The company is a global supplier of contact ...